PropertyValue
?:abstract
  • Amgen and Adaptive Biotechnologies will work together to identify and develop an antibody therapy for COVID-19 Adaptive aims to screen tens of thousands of antibodies produced by B cells in people who have recovered from COVID-19 and find ones that neutralize the virus that causes it, SARS-CoV-2 Amgen will develop and manufacture the best antibodies to test as therapies Adaptive is also expandinga collaboration with Microsoft to study how T cells respond to the viral infection
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Amgen pursues COVID-19 antibodies
?:type
?:who_covidence_id
  • #48051
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/hckwbzzw>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/hckwbzzw>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all